TAC方案用于乳腺癌新辅助化疗的疗效观察  

The dinical observation of neoadjuvant chemotherapy with TAC scheme in breast cancer

作　　者：郭文利[1] 喻其霞[1] 陈彩萍[1] 

机构地区：[1]嘉兴市第一医院乳腺科,浙江省嘉兴314000

出　　处：《中国基层医药》2012年第2期167-168,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨TAC方案在局部晚期乳腺癌患者术前新辅助化疗中的疗效。方法回顾性分析82例局部晚期乳腺癌患者临床资料，全部患者均接受TAC方案新辅助化疗，观察化疗后患者临床总有效率、近期毒副反应和手术情况。结果82例乳腺癌患者9例病理完全缓解（11.0％），21例达到CR（25．6％），47例达到PR（57．3％），14例达到SD（17．1％），临床总有效率82．9％。毒副反应主要以骨髓抑制为主，白细胞减少发生率达81．7％。其他不良反应还包括消化道症状和肝功能损害、脱发等。所有患者经对症处理后均可耐受。结论TAC方案新辅助化疗用于局部晚期乳腺癌患者可提高其治愈率．增加保乳机会。Objective To investigate clinical effects of neoadjuvant chemotherapy of TAC scheme in breast cancer. Methods 82 patients with locally advanced breast cancer receiving neoadjuvant TAC chemotherapy program were retrospectively analyzed. The total efficiency,toxicity,and recent surgical cases were evaluated. Results There were 21 cases of CR in 82 cases with breast cancer, accounting for 25.6% ,47 PR （57.3 % ）, 14 SD （ 17.1% ）, so the clinical total effective rate was 82.9%. The major toxic reactions was bone marrow suppression and neutropenia occurrence rate was 81.7%. Other adverse effects include gastrointestinal symptoms and liver dysfunction, and alopecia. All patients after symptomatic treatment can be tolerated. Conclusion TAC program neohdjavant chemotherapy for locally advanced breast cancer patients can improve the cure rate,increase breast-conserving opportunities.

关 键 词：乳腺肿瘤 化学疗法 辅助 

分 类 号：R737.9[医药卫生—肿瘤]